Biochemically-defined pools of amyloid-β in sporadic Alzheimer’s disease: correlation with amyloid PET

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · see citing works

Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · see citing works

Diffusible, nonfibrillar ligands derived from Aβ _1–42 are potent central nervous system neurotoxins

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279 · see citing works

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

Karran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · see citing works

Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · see citing works

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962 · see citing works

Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum.

Fujiki, Y., Hubbard, A. L., Fowler, S., & Lazarow, P. B. (1982) · The Journal of Cell Biology · doi:10.1083/jcb.93.1.97 · Cited by 1,754 · see citing works

Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism

Cohen, S. I. A., Linse, S. S., Luheshi, L. M., Hellstrand, E., White, D. A., Rajah, L., Otzen, D. E., Vendruscolo, M., Dobson, C. M., & Knowles, T. P. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218402110 · Cited by 1,410 · see citing works

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363 · see citing works

Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline

Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · see citing works

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

Ellis, K. A., Bush, A. I., Darby, D., Fazio, D. D., Foster, J. K., Hudson, P. J., Lautenschlager, N. T., Lenzo, N. P., Martins, R. N., Maruff, P. T., et al. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009405 · Cited by 970 · see citing works

Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850 · see citing works

Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide

Haass, C., & Selkoe, D. J. (1993) · Cell · doi:10.1016/0092-8674(93)90312-e · Cited by 833 · see citing works

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602 · see citing works

Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease

Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582 · see citing works

The Levels of Soluble versus Insoluble Brain Aβ Distinguish Alzheimer's Disease from Normal and Pathologic Aging

Wang, J., Dickson, D. W., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7085 · Cited by 567 · see citing works

Improvement of the solubilization of proteins in two‐dimensional electrophoresis with immobilized pH gradients

Rabilloud, T., Adessi, C., Giraudel, A., & Lunardi, J. (1997) · Electrophoresis · doi:10.1002/elps.1150180303 · Cited by 554 · see citing works

Relative Abundance of Alzheimer A Beta Amyloid Peptide Variants in Alzheimer Disease and normal Aging

Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., Roses, A. D., Tjernberg, L. O., Silberring, J., Gandy, S. E., Winblad, B., & Greengard, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8378 · Cited by 468 · see citing works

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. J. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 455 · see citing works

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography

Palmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400 · see citing works

Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain

Klunk, W. E., Lopresti, B. J., Ikonomović, M. D., Lefterov, I. M., Koldamova, R. P., Abrahamson, E. E., Debnath, M. L., Holt, D. P., Huang, G.-F., Shao, L., et al. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2990-05.2005 · Cited by 376 · see citing works

Amyloid Imaging with18F-Florbetaben in Alzheimer Disease and Other Dementias

Villemagne, V. L., Ong, K. T., Mulligan, R. S., Holl, G., Pejoska, S., Jones, G. R., O'Keefe, G. J., Ackerman, U., Tochon‐Danguy, H., Chan, J. G., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089730 · Cited by 374 · see citing works

Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease

Portelius, E., Bogdanovic, N., Gustavsson, M. K., Volkmann, I., Brinkmalm, G., Zetterberg, H., Winblad, B., & Blennow, K. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0690-1 · Cited by 348 · see citing works

The role of metallobiology and amyloid-β peptides in Alzheimer's disease

Roberts, B. R., Ryan, T. M., Bush, A. I., Masters, C. L., & Duce, J. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07500.x · Cited by 266 · see citing works

Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease

McColl, G., Roberts, B., Pukala, T., Kenche, V., Roberts, C., Link, C., Ryan, T., Masters, C., Barnham, K., Bush, A., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-57 · Cited by 256 · see citing works

β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia

Bourgeat, P., Chételat, G., Villemagne, V. L., Fripp, J., Raniga, P., Pike, K., Acosta, O., Szoeke, C., Ourselin, S., Ames, D., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c918b5 · Cited by 220 · see citing works

Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease

Shoji, M., Matsubara, E., Kanai, M., Watanabe, M., Nakamura, T., Tomidokoro, Y., Shizuka, M., Wakabayashi, K., Igeta, Y., Ikeda, Y., et al. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00122-1 · Cited by 219 · see citing works

Truncated beta‐amyloid peptide species in pre‐clinical Alzheimer's disease as new targets for the vaccination approach

Sergeant, N., Bombois, S., Ghestem, A., Drobecq, H., Kostanjevečki, V., Missiaen, C., Wattez, A., David, J. P., Vanmechelen, E., Sergheraert, C., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01818.x · Cited by 213 · see citing works

Adult-derived neural precursors transplanted into multiple regions in the adult brain

Herrera, D. G., García‐Verdugo, J. M., & Álvarez-Buylla, A. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6 · Cited by 204 · see citing works

Age and amyloid effects on human central nervous system amyloid‐beta kinetics

Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., Yarasheski, K., Sigurdson, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24454 · Cited by 200 · see citing works

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B. G., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159 · see citing works

Brain Uptake of Circulating Apolipoproteins J and E Complexed to Alzheimer′s Amyloid β

Zloković, B. V., Martel, C. L., Mačkić, J. B., Matsubara, E., Wısnıewskı, T., McComb, J. G., Frangione, B., & Ghiso, J. A. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2825 · Cited by 133 · see citing works

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease

Rembach, A., Faux, N. G., Watt, A. D., Pertile, K. K., Rumble, R. L., Trounson, B. O., Fowler, C. J., Roberts, B. R., Perez, K. A., Li, Q., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.006 · Cited by 132 · see citing works

Heat Shock Proteins and Amateur Chaperones in Amyloid-Beta Accumulation and Clearance in Alzheimer’s Disease

Wilhelmus, M. M. M., de Waal, R. M. W., & Verbeek, M. M. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0029-7 · Cited by 121 · see citing works

Alzheimer's Disease and the Amyloid β-Protein

Walsh, D. M., & Teplow, D. B. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385883-2.00012-6 · Cited by 120 · see citing works

Overlapping profiles of Aβ peptides in the Alzheimer's disease and pathological aging brains

Moore, B. D., Chakrabarty, P., Levites, Y., Kukar, T. L., Baine, A.-M. T., Moroni, T., Ladd, T. B., Das, P., Dickson, D. W., & Golde, T. E. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt121 · Cited by 112 · see citing works

Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases

Bilousova, T. V., Miller, C. A., Poon, W. W., Vinters, H. V., Corrada, M. M., Kawas, C. H., Hayden, E. Y., Teplow, D. B., Glabe, C. G., Albay, R., et al. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.09.018 · Cited by 112 · see citing works

Electrophoretic Separation of βA4 Peptides (1–40) and (1–42)

Klafki, H.-W., Wiltfang, J., & Staufenbiel, M. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0195 · Cited by 99 · see citing works

Mechanism of Neuronal versus Endothelial Cell Uptake of Alzheimer's Disease Amyloid β Protein

Kandimalla, K. K., Scott, O. G., Fulzele, S., Davidson, M. W., & Poduslo, J. F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004627 · Cited by 88 · see citing works

Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis

Rowe, C. C., & Villemagne, V. L. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.017 · Cited by 61 · see citing works

The effect of oxysterols on the interaction of Alzheimer's amyloid beta with model membranes

Phan, H. T. T., Hata, T., Morita, M., Yoda, T., Hamada, T., Vestergaard, M. C. M., & Takagi, M. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.021 · Cited by 55 · see citing works

Plasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden

Rembach, A., the AIBL Research Group, Watt, A. D., Wilson, W. J., Villemagne, V. L., Burnham, S. C., Ellis, K. A., Maruff, P., Ames, D., Rowe, C. C., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131802 · Cited by 48 · see citing works

En Attendant Centiloid

Villemagne, V. L. (2014) · Advances in Research · doi:10.9734/air/2014/11599 · Cited by 37 · see citing works

A distinct subfraction of Aβ is responsible for the high‐affinity Pittsburgh compound B‐binding site in Alzheimer's disease brain

Matveev, S. V., Spielmann, H. P., Metts, B. M., Chen, J., Onono, F. O., Zhu, H., Scheff, S. W., Walker, L. C., & LeVine, H. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12815 · Cited by 24 · see citing works

Biphasic Microreactor for Efficient Membrane Protein Pretreatment with a Combination of Formic Acid Assisted Solubilization, On-Column pH Adjustment, Reduction, Alkylation, and Tryptic Digestion

Zhao, Q., Liang, Y., Yuan, H., Sui, Z., Wu, Q., Liang, Z., Zhang, L., & Zhang, Y. (2013) · Analytical Chemistry · doi:10.1021/ac402076u · Cited by 21 · see citing works

Analysis of a compartmental model of amyloid beta production, irreversible loss and exchange in humans

Elbert, D. L., Patterson, B. W., & Bateman, R. J. (2014) · Mathematical Biosciences · doi:10.1016/j.mbs.2014.11.004 · Cited by 20 · see citing works

Binding of the Alzheimer amyloid β-peptide to neuronal cell membranes by fluorescence correlation spectroscopy

Hossain, S., Grande, M., Ahmadkhanov, G., & Pramanik, A. (2007) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2007.01.008 · Cited by 17 · see citing works

Untitled work

(1999) · doi:10.1002/1531-8249(199904)45:4

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · see citing works

A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain

Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808 · see citing works

Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes

Nortley, R., Korte, N., Izquierdo, P., Hirunpattarasilp, C., Mishra, A., Jaunmuktane, Z., Kyrargyri, V., Pfeiffer, T., Khennouf, L., Madry, C., et al. (2019) · Science · doi:10.1126/science.aav9518 · Cited by 682 · see citing works

Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies

Polanco, J. C., Li, C., Bodea, L., Martínez‐Mármol, R., Meunier, F. A., & Götz, J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.162 · Cited by 374 · see citing works

γ-Secretase in Alzheimer’s disease

Hur, J. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00754-8 · Cited by 325 · see citing works

Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer’s disease

Hadoux, X., Hui, F., Lim, J. K. H., Masters, C. L., Pébay, A., Chevalier, S., Ha, J. J., Loi, S. M., Fowler, C. J., Rowe, C. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12242-1 · Cited by 306 · see citing works

Aβ(1-42) tetramer and octamer structures reveal edge conductivity pores as a mechanism for membrane damage

Ciudad, S., Puig, E., Botzanowski, T., Meigooni, M., Arango, A. S., Do, J., Mayzel, M., Bayoumi, M., Chaignepain, S., Maglia, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16566-1 · Cited by 228 · see citing works

Quantification of amyloid PET for future clinical use: a state-of-the-art review

Pemberton, H. G., Collij, L. E., Heeman, F., Bollack, A., Shekari, M., Salvadó, G., Alves, I. L., Garcia, D. V., Battle, M., Buckley, C., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05784-y · Cited by 226 · see citing works

Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs

Alves, F. M., Kalinowski, P., & Ayton, S. (2023) · Neurology · doi:10.1212/wnl.0000000000207156 · Cited by 217 · see citing works

Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives

Kim, B., Kim, S., Nam, Y., Park, Y., Shin, S. M., & Moon, M. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00465-w · Cited by 150 · see citing works

Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies—Gains from AIBL and DIAN Cohort Studies

Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129 · see citing works

Microglial mTOR Activation Upregulates Trem2 and Enhances β-Amyloid Plaque Clearance in the 5XFAD Alzheimer's Disease Model

Shi, Q., Chang, C., Saliba, A., & Bhat, M. A. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.2427-21.2022 · Cited by 134 · see citing works

Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain

Genoud, S., Roberts, B. R., Gunn, A. P., Halliday, G. M., Lewis, S. J. G., Ball, H. J., Hare, D. J., & Double, K. L. (2017) · Metallomics · doi:10.1039/c7mt00244k · Cited by 126 · see citing works

Cu and Zn interactions with Aβ peptides: consequence of coordination on aggregation and formation of neurotoxic soluble Aβ oligomers

Rana, M., & Sharma, A. K. (2018) · Metallomics · doi:10.1039/c8mt00203g · Cited by 113 · see citing works

Comparison of ¹⁸F‐florbetaben quantification results using the standard Centiloid, MR‐based, and MR‐less CapAIBL^® approaches: Validation against histopathology

Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93 · see citing works

Alzheimer's disease pathophysiology in the Retina

Gaire, B. P., Koronyo, Y., Fuchs, D.-T. S., Shi, H., Rentsendorj, A., Danziger, R., Vit, J., Mirzaei, N., Doustar, J., Sheyn, J., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101273 · Cited by 102 · see citing works

Rapamycin and Alzheimer disease: a double-edged sword?

Carosi, J. M., & Sargeant, T. J. (2019) · Autophagy · doi:10.1080/15548627.2019.1615823 · Cited by 99 · see citing works

Soluble aggregates present in cerebrospinal fluid change in size and mechanism of toxicity during Alzheimer’s disease progression

De, S., Whiten, D. R., Ruggeri, F. S., Hughes, C. D., Rodrigues, M., Sideris, D. I., Taylor, C. G., Aprile, F. A., Muyldermans, S., Knowles, T. P. J., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0777-4 · Cited by 96 · see citing works

Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy

Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., & Bathla, G. (2023) · RadioGraphics · doi:10.1148/rg.230009 · Cited by 90 · see citing works

Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe

Iaccarino, L., Burnham, S. C., Dell’Agnello, G., Dowsett, S. A., & Epelbaum, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.43 · Cited by 81 · see citing works

Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation

Gomes, L. A., Uytterhoeven, V., Lopez-Sanmartin, D., Tomé, S. O., Tousseyn, T., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Verstreken, P., & Thal, D. R. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02251-6 · Cited by 74 · see citing works

Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age

Bergen, J. M. G. V., Li, X., Quevenco, F. C., Gietl, A. F., Treyer, V., Meyer, R., Buck, A., Kaufmann, P. A., Nitsch, R. M., van Zijl, P. C. M., et al. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.03.021 · Cited by 75 · see citing works

Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy

Belder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., Barkhof, F., & Fox, N. C. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00335-1 · Cited by 77 · see citing works

Quantitative Susceptibility Mapping of Brain Iron and β-Amyloid in MRI and PET Relating to Cognitive Performance in Cognitively Normal Older Adults

Chen, L., Soldan, A., Oishi, K., Faria, A. V., Zhu, Y., Albert, M., van Zijl, P. C. M., & Li, X. (2020) · Radiology · doi:10.1148/radiol.2020201603 · Cited by 71 · see citing works

Autophagy Modulation as a Treatment of Amyloid Diseases

Mputhia, Z., Hone, E., Tripathi, T., Sargeant, T. J., Martins, R. N., & Bharadwaj, P. (2019) · Molecules · doi:10.3390/molecules24183372 · Cited by 69 · see citing works

Disturbances of sleep quality, timing and structure and their relationship with other neuropsychiatric symptoms in Alzheimer’s disease and schizophrenia: Insights from studies in patient populations and animal models

Winsky‐Sommerer, R., de Oliveira, P., Loomis, S., Wafford, K. A., Dijk, D., & Gilmour, G. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.027 · Cited by 66 · see citing works

Selective Secretase Targeting for Alzheimer’s Disease Therapy

Miranda, A., Montiel, E., Ulrich, H., & Paz, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201027 · Cited by 66 · see citing works

Retinal Functional and Structural Changes in the 5xFAD Mouse Model of Alzheimer’s Disease

Lim, J. K. H., Li, Q.-X., He, Z., Vingrys, A. J., Chinnery, H. R., Mullen, J., Bui, B. V., & Nguyen, C. T. O. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00862 · Cited by 65 · see citing works

Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression

Liebsch, F., Kulic, L., Teunissen, C. E., Shobo, A., Ulku, I., Engelschalt, V., Hancock, M. A., van der Flier, W. M., Kunach, P., Rosa‐Neto, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10152-w · Cited by 64 · see citing works

Imaging protein aggregates in the serum and cerebrospinal fluid in Parkinson’s disease

Lobanova, E., Whiten, D. R., Ruggeri, F. S., Taylor, C. G., Kouli, A., Xia, Z., Emin, D., Zhang, Y. P., Lam, J. Y. L., Williams‐Gray, C. H., et al. (2021) · Brain · doi:10.1093/brain/awab306 · Cited by 63 · see citing works

The mTOR–lysosome axis at the centre of ageing

Carosi, J. M., Fourrier, C., Bensalem, J., & Sargeant, T. J. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13347 · Cited by 66 · see citing works

Secondary prevention of Alzheimer’s dementia: neuroimaging contributions

ten Kate, M., Ingala, S., Schwarz, A. J., Fox, N. C., Chételat, G., van Berckel, B. N. M., Ewers, M., Foley, C., Gispert, J. D., Hill, D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0438-z · Cited by 60 · see citing works

The Aβ(1–38) peptide is a negative regulator of the Aβ(1–42) peptide implicated in Alzheimer disease progression

Quartey, M. O., Nyarko, J. N. K., Maley, J. M., Barnes, J. R., Bolanos, M. A. C., Heistad, R. M., Knudsen, K. J., Pennington, P. R., Buttigieg, J. A., de Carvalho, C. E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80164-w · Cited by 53 · see citing works

Physiological clearance of Aβ by spleen and splenectomy aggravates Alzheimer‐type pathogenesis

Yu, Z., Chen, D., Tan, C., Zeng, G., He, C.-Y., Wang, J., Bu, X., & Wang, Y. (2021) · Aging Cell · doi:10.1111/acel.13533 · Cited by 50 · see citing works

The emerging role of PET imaging in dementia

Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 51 · see citing works

Quantification of N-terminal amyloid-β isoforms reveals isomers are the most abundant form of the amyloid-β peptide in sporadic Alzheimer’s disease

Mukherjee, S., Perez, K. A., Lago, L., Klatt, S., McLean, C., Birchall, I. E., Barnham, K. J., Masters, C. L., & Roberts, B. R. (2021) · Brain Communications · doi:10.1093/braincomms/fcab028 · Cited by 50 · see citing works

Neuronal spreading and plaque induction of intracellular Aβ and its disruption of Aβ homeostasis

Roos, T. T., Garcia, M. G., Martinsson, I., Mabrouk, R., Israelsson, B., Deierborg, T., Kobro‐Flatmoen, A., Tanila, H., & Gouras, G. K. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02345-9 · Cited by 47 · see citing works

β-amyloid: The known unknowns

Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45 · see citing works

Early Intervention in Alzheimer’s Disease: How Early is Early Enough?

Fan, D., & Wang, Y.-J. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00429-x · Cited by 47 · see citing works

Endothelial leakiness elicited by amyloid protein aggregation

Li, Y., Ni, N., Lee, M., Wei, W., Andrikopoulos, N., Käkinen, A., Davis, T. P., Song, Y., Ding, F., Leong, D. T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44814-1 · Cited by 47 · see citing works

Rapamycin and Alzheimer disease: a hypothesis for the effective use of rapamycin for treatment of neurodegenerative disease

Carosi, J. M., & Sargeant, T. J. (2023) · Autophagy · doi:10.1080/15548627.2023.2175569 · Cited by 41 · see citing works

Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia

Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0837-9 · Cited by 43 · see citing works

The Validation of Multifactor Model of Plasma Aβ42 and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease

Jiao, F., Yi, F., Wang, Y., Zhang, S., Guo, Y., Du, W., Gao, Y., Ren, J., Zhang, H., Liu, L., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00212 · Cited by 40 · see citing works

Brain volume loss due to donanemab

Ayton, S. (2021) · European Journal of Neurology · doi:10.1111/ene.15007 · Cited by 33 · see citing works

What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies

Villemagne, V. L., Lopresti, B. J., Doré, V., Tudorascu, D., Ikonomović, M. D., Burnham, S. C., Minhas, D. S., Pascoal, T. A., Mason, N. S., Snitz, B. E., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.245423 · Cited by 35 · see citing works

Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local β-amyloid, Tau, and APOE4

Quevenco, F. C., Bergen, J. M. G. V., Treyer, V., Studer, S. T., Kagerer, S. M., Meyer, R., Gietl, A. F., Kaufmann, P. A., Nitsch, R. M., Höck, C., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00046 · Cited by 33 · see citing works

Plasma p‐tau181/Aβ 1‐42 ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ 1‐42 and future cognitive decline

Fowler, C. J., Stoops, E., Rainey‐Smith, S. R., Vanmechelen, E., Vanbrabant, J., Dewit, N., Mauroo, K., Maruff, P. T., Rowe, C. C., Fripp, J., et al. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12375 · Cited by 35 · see citing works

SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

Pradier, L., Blanchard-Brégeon, V., Bohme, A., Debeir, T., Ménager, J., Benoit, P., Barnéoud, P., Taupin, V., Bertrand, P., Dugay, P., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0447-y · Cited by 34 · see citing works

Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer’s Disease

Chatterjee, P., Doré, V., Pedrini, S., Krishnadas, N., Thota, R. N., Bourgeat, P., Ikonomović, M. D., Rainey‐Smith, S. R., Burnham, S. C., Fowler, C. J., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220908 · Cited by 35 · see citing works

Modulation of amyloid-β aggregation by metal complexes with a dual binding mode and their delivery across the blood–brain barrier using focused ultrasound

Chan, T. G., Rühl, C. L., Morse, S. V., Simon, M., Rakers, V., Watts, H. R., Aprile, F. A., Choi, J. J., & Vilar, R. (2021) · Chemical Science · doi:10.1039/d1sc02273c · Cited by 33 · see citing works

Longitudinal evaluation of the natural history of amyloid-β in plasma and brain

Burnham, S. C., Fandos, N., Fowler, C. J., Pérez‐Grijalba, V., Doré, V., Doecke, J. D., Shishegar, R., Cox, T. O., Fripp, J., Rowe, C. C., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa041 · Cited by 32 · see citing works

Oligopeptides Generated by Neprilysin Degradation of β-Amyloid Have the Highest Cu(II) Affinity in the Whole Aβ Family

Bossak‐Ahmad, K., Mital, M., Płonka, D., Drew, S. C., & Bal, W. (2018) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b03051 · Cited by 32 · see citing works

Cerebral amyloid‐β load is associated with neurodegeneration and gliosis: Mediation by p‐tau and interactions with risk factors early in the Alzheimer's continuum

Salvadó, G., Milà‐Alomà, M., Shekari, M., Minguillón, C., Fauria, K., Niñerola‐Baizán, A., Perissinotti, A., Kollmorgen, G., Buckley, C. J., Farrar, G., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12245 · Cited by 28 · see citing works

Citrullination of Amyloid-β Peptides in Alzheimer’s Disease

Mukherjee, S., Perez, K. A., Dubois, C., Nisbet, R. M., Li, Q., Varghese, S., Jin, L., Birchall, I. E., Streltsov, V. A., Vella, L. J., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00474 · Cited by 29 · see citing works

Amylin in Alzheimer's disease: Pathological peptide or potential treatment?

Mietlicki‐Baase, E. G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.016 · Cited by 29 · see citing works

Trans-Chalcone Plus Baicalein Synergistically Reduce Intracellular Amyloid Beta (Aβ42) and Protect from Aβ42 Induced Oxidative Damage in Yeast Models of Alzheimer’s Disease

Dhakal, S., Ramsland, P. A., Adhikari, B., & Macreadie, I. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179456 · Cited by 29 · see citing works

The β‐secretase (BACE) inhibitor NB‐360 in preclinical models: From amyloid‐β reduction to downstream disease‐relevant effects

Neumann, U., Machauer, R., & Shimshek, D. R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14582 · Cited by 27 · see citing works

Impact of Acute and Chronic Amyloid-β Peptide Exposure on Gut Microbial Commensals in the Mouse

Guilherme, M. D. S., Todorov, H., Osterhof, C., Möllerke, A., Cub, K., Hankeln, T., Gerber, S., & Endres, K. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01008 · Cited by 29 · see citing works

Tumour necrosis factor induces increased production of extracellular amyloid-β- and α-synuclein-containing aggregates by human Alzheimer’s disease neurons

Whiten, D. R., Brownjohn, P. W., Moore, S., De, S., Strano, A., Zuo, Y., Haneklaus, M., Klenerman, D., & Livesey, F. J. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa146 · Cited by 27 · see citing works

Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease

Chen, C. D., Joseph‐Mathurin, N., Sinha, N., Zhou, A., Li, Y., Friedrichsen, K. A., McCullough, A. A., Franklin, E. E., Hornbeck, R. C., Gordon, B. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02342-y · Cited by 27 · see citing works

Correction to: Different aspects of Alzheimer’s disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia

Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01005-5 · Cited by 25 · see citing works

Caenorhabditis elegans as a possible model to screen anti-Alzheimer's therapeutics

Paul, D., Chipurupalli, S., Justin, A., Raja, K., & Mohankumar, S. K. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106932 · Cited by 25 · see citing works

Alternative Targets to Fight Alzheimer’s Disease: Focus on Astrocytes

Valenza, M., Facchinetti, R., Menegoni, G., Steardo, L., & Scuderi, C. (2021) · Biomolecules · doi:10.3390/biom11040600 · Cited by 25 · see citing works

Genome-wide association study of brain biochemical phenotypes reveals distinct genetic architecture of Alzheimer’s disease related proteins

Oatman, S. R., Reddy, J. S., Quicksall, Z., Carrasquillo, M. M., Wang, X., Liu, C., Yamazaki, Y., Nguyen, T., Malphrus, K. G., Heckman, M. G., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00592-2 · Cited by 25 · see citing works

A combined physiologically‐based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease

Geerts, H., Walker, M., Rose, R., Bergeler, S., van der Graaf, P. H., Schuck, E. L., Koyama, A., Yasuda, S., Hussein, Z., Reyderman, L., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12912 · Cited by 23 · see citing works

Brain amyloid burden and cerebrovascular disease are synergistically associated with neurometabolism in cognitively unimpaired older adults

Schreiner, S. J., Kirchner, T., Narkhede, A., Wyss, M., Bergen, J. M. G. V., Steininger, S. C., Gietl, A. F., Leh, S. E., Treyer, V., Buck, A., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.004 · Cited by 24 · see citing works

Quantitative proteomics of tau and Aβ in detergent fractions from Alzheimer's disease brains

Mukherjee, S., Dubois, C., Perez, K. A., Varghese, S., Birchall, I. E., Leckey, M., Davydova, N., McLean, C., Nisbet, R. M., Roberts, B. R., et al. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15713 · Cited by 21 · see citing works

Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer’s disease

Aljuhani, M., Ashraf, A., & Edison, P. (2024) · Brain Communications · doi:10.1093/braincomms/fcae435 · Cited by 22 · see citing works

Age, sex and APOE-ε4 modify the balance between soluble and fibrillar β-amyloid in non-demented individuals: topographical patterns across two independent cohorts

Cacciaglia, R., Salvadó, G., Molinuevo, J. L., Shekari, M., Falcón, C., Operto, G., Suárez‐Calvet, M., Milà‐Alomà, M., Sala, A., Rodriguez‐Vieitez, E., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01436-7 · Cited by 23 · see citing works

Differential regulation of insulin signalling by monomeric and oligomeric amyloid beta-peptide

Molina-Fernández, R., Picón-Pagès, P., Barranco-Almohalla, A., Crepin, G., Herrera-Fernández, V., García-Elías, A., Fanlo-Ucar, H., Fernàndez‐Busquets, X., García‐Ojalvo, J., Oliva, B., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac243 · Cited by 23 · see citing works

The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention

Tolar, M., Hey, J. A., Power, A., & Abushakra, S. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052727 · Cited by 22 · see citing works

An Overview of Several Inhibitors for Alzheimer’s Disease: Characterization and Failure

Boopathi, S., Poma, A. B., & Garduño‐Juárez, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910798 · Cited by 20 · see citing works

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates

Ramakrishnan, V., Friedrich, C. M., Witt, C. M., Sheehan, R., Pryor, M. M., Atwal, J. K., Wildsmith, K. R., Kudrycki, K., Lee, S., Mazer, N. A., et al. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12876 · Cited by 19 · see citing works

Patients with Alzheimer’s disease have an increased removal rate of soluble beta-amyloid-42

Zaretsky, D. V., Zaretskaia, M. V., Molkov, Y. I., & Initiative, A. D. N. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276933 · Cited by 22 · see citing works

Tyramine and Amyloid Beta 42: A Toxic Synergy

Dhakal, S., & Macreadie, I. G. (2020) · Biomedicines · doi:10.3390/biomedicines8060145 · Cited by 20 · see citing works

Stabilization of a Membrane-Associated Amyloid-β Oligomer for Its Validation in Alzheimer's Disease

Serra-Batiste, M., Tolchard, J. L., Giusti, F., Zoonens, M. A., & Carulla, N. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00038 · Cited by 16 · see citing works

CARD9 attenuates Aβ pathology and modifies microglial responses in an Alzheimer’s disease mouse model

Ennerfelt, H. E., Holliday, C., Shapiro, D. A., Zengeler, K. E., Bolte, A. C., Ulland, T., & Lukens, J. R. (2023) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2303760120 · Cited by 15 · see citing works

Endogenous Human Proteins Interfering with Amyloid Formation

Gharibyan, A. L., Jayaweera, S. W., Lehmann, M., Anan, I., & Olofsson, A. (2022) · Biomolecules · doi:10.3390/biom12030446 · Cited by 17 · see citing works

Mass spectrometric studies of the variety of beta‐amyloid proteoforms in Alzheimer's disease

Zakharova, N. V., Kononikhin, A. S., Indeykina, M. I., Bugrova, A. E., Strelnikova, P. A., Игоревич, П. С., Kozin, S. A., Popov, I. A., Mitkevich, V. A., Makarov, A. А., et al. (2022) · Mass Spectrometry Reviews · doi:10.1002/mas.21775 · Cited by 16 · see citing works

Synthetic, Cell-Derived, Brain-Derived, and Recombinant β-Amyloid: Modelling Alzheimer’s Disease for Research and Drug Development

Varshavskaya, K. B., Mitkevich, V. A., Makarov, A. А., & Barykin, E. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315036 · Cited by 16 · see citing works

Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity

Mastenbroek, S. E., Sala, A., García, D. V., Shekari, M., Salvadó, G., Lorenzini, L., Pieperhoff, L., Wink, A. M., Alves, I. L., Wolz, R., et al. (2024) · Neurology · doi:10.1212/wnl.0000000000209419 · Cited by 16 · see citing works

Increased cerebral blood volume in small arterial vessels is a correlate of amyloid-β–related cognitive decline

Hua, J., Lee, S. W., Blair, N. I. S., Wyss, M., Bergen, J. M. G. V., Schreiner, S. J., Kagerer, S. M., Leh, S. E., Gietl, A. F., Treyer, V., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.01.001 · Cited by 14 · see citing works

Enhanced ion mobility resolution of Abeta isomers from human brain using high-resolution demultiplexing software

Mukherjee, S., Fjeldsted, J. C., Masters, C. L., & Roberts, B. R. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04055-x · Cited by 14 · see citing works

A Systematic Bioinformatics Workflow With Meta-Analytics Identified Potential Pathogenic Factors of Alzheimer’s Disease

Yuen, S. C., Zhu, H., & Leung, S.-W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00209 · Cited by 15 · see citing works

Recent Research Progress in Fluorescent Probes for Detection of Amyloid-β In Vivo

Zhang, Z.-Y., Li, Z., Tang, Y.-H., Xu, L., Zhang, D., Qin, T., & Wang, Y. (2023) · Biosensors · doi:10.3390/bios13110990 · Cited by 13 · see citing works

The development of near-infrared hydrogen sulfide probes and its application in the past ten years

Li, Y., Nouman, N. M., Yin, C., & Huo, F. (2024) · Dyes and Pigments · doi:10.1016/j.dyepig.2024.112246 · Cited by 13 · see citing works

Apolipoprotein B gene expression and regulation in relation to Alzheimer’s disease pathophysiology

Aumont‐Rodrigue, G., Picard, C., Labonté, A., & Poirier, J. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100667 · Cited by 13 · see citing works

Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age

Kagerer, S. M., Schroeder, C., Bergen, J. M. G. V., Schreiner, S. J., Meyer, R., Steininger, S. C., Vionnet, L., Gietl, A. F., Treyer, V., Buck, A., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.811146 · Cited by 13 · see citing works

Protein Self-Assembly at the Liquid–Surface Interface. Surface-Mediated Aggregation Catalysis

Lyubchenko, Y. L. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c09029 · Cited by 11 · see citing works

Cognitive reserve and Alzheimer's biological continuum: clues for prediction and prevention of dementia

Martorana, A., Assogna, M., Lucia, V. D., Motta, C., Bonomi, C. G., Bernocchi, F., Donna, M. G. D., & Koch, G. (2021) · Minerva Medica · doi:10.23736/s0026-4806.21.07448-6 · Cited by 11 · see citing works

Upregulation of endocytic protein expression in the Alzheimer’s disease male human brain

Alsaqati, M., Thomas, R. S., & Kidd, E. J. (2023) · Aging Brain · doi:10.1016/j.nbas.2023.100084 · Cited by 10 · see citing works

Novel Amylin Analogues Reduce Amyloid-β Cross-Seeding Aggregation and Neurotoxicity

Dharmaraj, G. L., Arigo, F. D., Young, K. A., Martins, R. N., Mancera, R. L., & Bharadwaj, P. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215339 · Cited by 9 · see citing works

Exploring tau protein and amyloid-beta propagation: A sensitivity analysis of mathematical models based on biological data

Corti, M. (2024) · Brain Multiphysics · doi:10.1016/j.brain.2024.100098 · Cited by 8 · see citing works

Interactions between daily sleep-wake rhythms, γ-secretase, and amyloid-β peptide pathology point to complex underlying relationships

Turton, S. M., Padgett, S., Jessup, M. T., Johnson, C. E., Buzinova, V. A., Barth, S. E., Köhler, K., Spearman, H. M., Macheda, T., Manauis, E. C., et al. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167840 · Cited by 7 · see citing works

Insights into Membrane Damage by α-Helical and β-Sheet Peptides

Rangubpit, W., Distaffen, H. E., Nilsson, B. L., & Dias, C. L. (2025) · Biomolecules · doi:10.3390/biom15070973 · Cited by 8 · see citing works

Modifying Dietary Protein Impacts mTOR Signaling and Brain Deposition of Amyloid β in a Knock-In Mouse Model of Alzheimer Disease

Bensalem, J., Hein, L. K., Hassiotis, S., Trim, P. J., Proud, C. G., Heilbronn, L. K., & Sargeant, T. J. (2023) · Journal of Nutrition · doi:10.1016/j.tjnut.2023.02.035 · Cited by 8 · see citing works

Polyphenol-Peptide Interactions in Mitigation of Alzheimer’s Disease: Role of Biosurface-Induced Aggregation

Gaudreault, R., Hervé, V., van de Ven, T. G. M., Mousseau, N., & Ramassamy, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201549 · Cited by 8 · see citing works

Early divergent modulation of NLRP2′s and NLRP3′s inflammasome sensors vs. AIM2′s one by signals from Aβ·Calcium-sensing receptor complexes in human astrocytes

Chiarini, A., Armato, U., Gui, L., Yin, M., Chang, S., & Prà, I. D. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149283 · Cited by 7 · see citing works

Phytochemical Compounds Loaded to Nanocarriers as Potential Therapeutic Substances for Alzheimer’s Disease-Could They be Effective?

Polat, D. Ç., Karadağ, A. E., Köprülü, R. E. P., Karantas, I. D., Mutlu, G., Çağlar, E. Ş., Okur, M. E., Okur, N. Ü., & Siafaka, P. I. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220411104128 · Cited by 7 · see citing works

Unveiling the Therapeutic Potential of Kelulut (Stingless Bee) Honey in Alzheimer’s Disease: Findings from a Rat Model Study

Shaikh, A., Ahmad, F., Teoh, S. L., Kumar, J., & Yahaya, M. F. (2024) · Antioxidants · doi:10.3390/antiox13080926 · Cited by 10 · see citing works

Distinct Pools of ␤-Amyloid in Alzheimer Disease–Affected Brain

Steinerman, J. R., Irizarry, M. C., Scarmeas, N., Raju, S., Brandt, J., Albert, M., Blacker, D., Hyman, B. T., & Stern, Y. (2022) · doi:10.7916/j0pe-r896

Spatial pattern of beta-amyloid accumulation in Alzheimer’s disease as measured with positron emission tomography

Guo, T. (2018) · mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich)

Amyloid (B-protein (Aß) Accumulation in the Putamen and Mammillary Body during Aging and in Alzheimer Disease

Nakabayash, J., Yoshimura, M., Morishima‐Kawashima, M., Funato, H., Miyakawa, T., Yamazaki, T., & Ihara, Y. (1998) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199804000-00007 · Cited by 26 · see citing works

Distinct Pools of β-Amyloid in Alzheimer Disease-Affected Brain: A Clinicopathologic Study

Steinerman, J. R., Irizarry, M., Scarmeas, N., Raju, S., Brandt, J., Albert, M., Blacker, D., Hyman, B. T., & Stern, Y. (2008) · JAMA Neurology · doi:10.7916/d8ht2p4s

Distribution of isomerized and racemized amyloid β isoforms in sporadic Alzheimer’s disease using ion‐mobility mass spectrometry

Mukherjee, S., Perez, K. A., Lago, L., Klatt, S., Birchall, I. E., Barnham, K. J., Masters, C. L., & Roberts, B. R. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.039256